$6.88
-0.01-0.15%
Last update: Nov 11, 4:38 PM
Cartesian Therapeutics Inc (RNAC) Stock Price, Quote, News & History
RNACNASDAQ
Cartesian Therapeutics gains after licensing an in vivo CAR-T platform from WestGene, with a myasthenia gravis trial planned for 2026.
You can purchase shares of Cartesian Therapeutics (NASDAQ:RNAC) through any online brokerage.
Other companies in Cartesian Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Cartesian Therapeutics has a consensus price target of $36.11.
The stock price for Cartesian Therapeutics (NASDAQ: RNAC) is $6.75 last updated November 11, 2026 at 4:38 PM EST.
There are no upcoming dividends for Cartesian Therapeutics.
Cartesian Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Cartesian Therapeutics.
Cartesian Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic...
